TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL
Study: NCT01534962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 112 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Oral administration, BID; for a maximum of 112 days.
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 1
Description: Buffering agent: N/A Isotonic agent: NaCl 9.0 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
Study: NCT04024059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for adherence
Description: Incentives contingent on buprenorphine adherence
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL
Study: NCT04024059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for adherence
Description: Incentives contingent on buprenorphine adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management for abstinence
Description: Incentives contingent on opiate abstinence
Study: NCT01497535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Study: NCT01534962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, BID; for a maximum of 112 days.
Study: NCT05509036

Intervention type: OTHER
Intervention: No interventions
Description: No interventions
Study: NCT01760460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for anacetrapib
Study: NCT00651352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg nicotine lozenge
Description: marketed formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 mg nicotine lozenge
Description: marketed formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine prototype
Description: 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine prototype
Description: 4 mg
Study: NCT00282984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 mg placebo twice daily by mouth for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg twice daily by mouth for 12 weeks
Study: NCT04802317

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of the composition of the intestinal microbiota
Description: Identification of the composition of the intestinal microbiota

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of the composition of the intestinal microbiota
Description: Identification of the composition of the intestinal microbiota

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of the composition of the intestinal microbiota
Description: Identification of the composition of the intestinal microbiota
Study: NCT05808114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friends program
Description: A GCBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions
Study: NCT01497535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
Study: NCT00614653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV Over 90 Minutes Every 2 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 100 mg by mouth Once Daily on days with radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 400 mg/m\^2 PO Twice Daily on days with radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
Study: NCT02729077

Intervention type: DEVICE
Intervention: Pulse Oximetry
Description: Use of pulse oximetry device for 48 hours after surgery.

Intervention type: DEVICE
Intervention: Pulse Oximetry
Description: Use of pulse oximetry device for 48 hours after surgery.
Study: NCT00187629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietary phosphorus
Description: varying amts dietary phosphorus

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary phosphorus
Description: varying amts dietary phosphorus
Study: NCT01943422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Interferon alfa-2b
Description: •Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Interferon alfa-2b
Description: •Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Interferon alfa-2b
Description: •Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene.
Study: NCT03520439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Study: NCT03954314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
Study: NCT00999765

Intervention type: BEHAVIORAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: eight-week (two hours a week) group therapy (8-12 patients per group)
Study: NCT00679536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m\^2/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
Study: NCT04304365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up clinic visit
Description: Participants will be scheduled for a visit with a provider in 1-2 weeks that will include an ultrasound examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text message
Description: Participants will be instructed that they will be contacted by research staff through text message 14 days after the initial visit. They will receive a survey link through text message at this time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sensitivity Pregnancy Test (LSPT)
Description: Participants will be instructed on how to test their urine 14 days after the medication abortion for continued pregnancy. LSPT can detect hCG levels as low as 2000 mIU/ml.
Study: NCT03795714

Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS or OCT and Invasive physiologic indices
Description: IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
Study: NCT01776463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04476966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bladogra
Description: 1 tablet contains 25 mg Mirabegron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrbetriq (first dosing)
Description: 1 tablet contains 25 mg Mirabegron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myrbetriq (second dosing)
Description: 1 tablet contains 25 mg Mirabegron
Study: NCT01006941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: 2500 ova per dose, orally, every second week, during 12 weeks
Study: NCT03735134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Loading Dose
Description: Two milligrams of colchicine will be administrated in addition to the standard of care treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Loading Dose
Description: Two milligrams of colchicine will be administrated in addition to the standard of care treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment prior to elective PCI
Description: All medications normally given to patients prior to elective PCI
Study: NCT00618930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moviprep®
Description: use of Moviprep®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Use of Fleet
Study: NCT01043120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Barusiban
Description: IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
Study: NCT03373136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypectomy
Description: Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy
Description: Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
Study: NCT02128217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
Study: NCT02098096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Work
Description: Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~1. Familiarization~2. Acclimatization~3. Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
Study: NCT02273687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivid S6 GE Ultrasound
Description: Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe.
Study: NCT00971841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03192241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump
Description: Intervention is providing mothers with a manual breast pump and instructions for when it could be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Book
Description: Active control intervention is providing mother's with a children's book and information about reading to baby.
Study: NCT00706381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sincalide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sincalide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sincalide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sincalide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Meal
Description: 600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Meal
Description: 600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Meal
Description: 600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Meal
Description: 600 calorie meal containing 72% fat, 8% protein, and 20% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carb meal
Description: 600 calorie meal containing 100% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carb meal
Description: 600 calorie meal containing 100% carbohydrate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carb meal
Description: 600 calorie meal containing 100% carbohydrate
Study: NCT03786042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette ad exposure
Description: Participants view a series of e-cigarette TV commercials

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non e-cigarette TV commercials
Description: Participants view a series of non e-cigarette TV commercials
Study: NCT04487600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active voiding trial
Study: NCT04482725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 2
Description: Buffering agent: Disodium hydrogen phosphate, dihydrate 1.42 mg/mL Isotonic agent: NaCl 8.25 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trial product 3
Description: Buffering agent: Disodium hydrogen phosphate dihydrate 1.42 mg/mL Isotonic agent: Propylene glycol 18.5 mg/mL
Study: NCT03520439

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
Study: NCT02825433

Intervention type: OTHER
Intervention: No intervention, only ventilation monitoring
Study: NCT02789449

Intervention type: OTHER
Intervention: assessment of DLNO and DLCO

Intervention type: OTHER
Intervention: assessment of DLNO and DLCO